Zevtera: a new cephalosporin antibiotic

Basilea has launched Zevtera (ceftobiprole), a new intravenous antibiotic for the treatment of pneumonia.

Ceftobiprole (Zevtera) is active against multiple pathogens, including MRSA.
Ceftobiprole (Zevtera) is active against multiple pathogens, including MRSA.

Zevtera (ceftobiprole) is a broad-spectrum cephalosporin antibiotic indicated for the treatment of community- and hospital-acquired pneumonia (excluding ventilator-associated pneumonia).

Further information
View Zevtera drug record 
Summary of Product Characteristics
Manufacturer: Basilea

Ceftobiprole medocaril sodium, the active ingredient of Zevtera, is the prodrug of ceftobiprole. Similar to other beta lactams, ceftobiprole is bactericidal and works by binding to penicillin-binding proteins in susceptible species, inhibiting synthesis of the peptidoglycan cell wall. Ceftobiprole is inactive against Enterobacteriaceae, Acinetobacter and P. aeruginosa strains that express β-lactamases of Ambler class A, B or D. 

Ceftobiprole is administered as a 500mg intravenous infusion over 2 hours every 8 hours. In community-acquired pneumonia it may be suitable to switch the patient to an oral antibiotic after at least 3 days of ceftobiprole treatment, depending on their response. 

The most common adverse effects of ceftobiprole are nausea, vomiting, diarrhoea, infusion site reactions, hypersensitivity and dysgeusia.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases